Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

34
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

752
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
752
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

619
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
619
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

334
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
334
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

350
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
350

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis.

Journal of hepatology·2026
Same author

Peak-MELD scores, a disease trajectory associated with reduced access to liver transplantation.

Frontiers in medicine·2026
Same author

Propensity Score-matched Real-world Data: HCC Recurrence Rates After DBD Liver Transplantation in Times of Machine Perfusion.

Transplantation direct·2026
Same author

Post-TIPS Dynamics of von Willebrand Factor for Risk Stratification After TIPS Placement.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

A Retrospective Multicenter Study Identifies a Similar Overall Survival of Patients After Liver Transplantation With Incidental Cholangiocarcinoma Compared to Hepatocellular Carcinoma.

Clinical transplantation·2026
Same author

Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma-Data From the Multinational LITCHI Registry.

Liver international : official journal of the International Association for the Study of the Liver·2026

Related Experiment Video

Updated: Mar 27, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

[Current management of hepatitis C].

Christian M Lange

    Medizinische Monatsschrift Fur Pharmazeuten
    |January 7, 2016
    PubMed
    Summary

    Directly acting antiviral agents (DAAs) have revolutionized hepatitis C virus (HCV) treatment, enabling high cure rates. Current recommendations focus on DAA combinations for managing chronic HCV infection.

    Area of Science:

    • Hepatology and Viral Gastroenterology
    • Pharmacology and Therapeutics

    More Related Videos

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.8K
    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
    10:28

    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

    Published on: June 26, 2020

    10.4K

    Related Experiment Videos

    Last Updated: Mar 27, 2026

    A Protocol for Analyzing Hepatitis C Virus Replication
    13:04

    A Protocol for Analyzing Hepatitis C Virus Replication

    Published on: June 26, 2014

    24.8K
    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.8K
    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
    10:28

    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

    Published on: June 26, 2020

    10.4K